Trials / Terminated
TerminatedNCT03608618
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- MaxCyte, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy. The study will also assess multiple cycles of treatment and adding preconditioning with cyclophosphamide.
Conditions
- Peritoneal Mesothelioma
- Fallopian Tube Adenocarcinoma
- Adenocarcinoma of the Ovary
- Primary Peritoneal Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MCY-M11 | Intraperitoneal administration |
| DRUG | Cyclophosphamide | Intravenous administration for preconditioning |
Timeline
- Start date
- 2018-08-27
- Primary completion
- 2021-02-11
- Completion
- 2021-08-24
- First posted
- 2018-08-01
- Last updated
- 2021-09-05
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03608618. Inclusion in this directory is not an endorsement.